Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib in advanced soft tissue sarcoma
NCT00753688Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2008
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in soft tissue sarcoma (STS) comparing Pazopanib with Placebo (2 arms). Primary endpoint: Progression-free Survival at 10 months. Started Oct 2008; status: completed.
02
Drugs
pazopanib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT00753688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00753688.